Harmonised relative effectiveness discussions moving ahead in Europe
This article was originally published in Scrip
Support for a single European relative effectiveness assessment done by the European Medicines Agency (EMA) is gaining momentum with the pharmaceutical industry, said Andrew Witty, president of the European pharmaceutical industry federation EFPIA at its annual meeting in London this week.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.